nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprenolol—ADRB3—polycystic ovary syndrome	0.626	0.724	CbGaD
Alprenolol—ADRB2—polycystic ovary syndrome	0.238	0.275	CbGaD
Alprenolol—Pindolol—ADRB3—polycystic ovary syndrome	0.000847	0.14	CrCbGaD
Alprenolol—Metipranolol—ADRB2—polycystic ovary syndrome	0.000645	0.106	CrCbGaD
Alprenolol—Esmolol—ADRB2—polycystic ovary syndrome	0.000512	0.0844	CrCbGaD
Alprenolol—Propranolol—ADRB3—polycystic ovary syndrome	0.000462	0.0762	CrCbGaD
Alprenolol—Betaxolol—ADRB2—polycystic ovary syndrome	0.000451	0.0743	CrCbGaD
Alprenolol—Atenolol—ADRB2—polycystic ovary syndrome	0.000447	0.0737	CrCbGaD
Alprenolol—Penbutolol—ADRB2—polycystic ovary syndrome	0.000447	0.0737	CrCbGaD
Alprenolol—Bisoprolol—ADRB2—polycystic ovary syndrome	0.000435	0.0718	CrCbGaD
Alprenolol—Acebutolol—ADRB2—polycystic ovary syndrome	0.000412	0.068	CrCbGaD
Alprenolol—Oxprenolol—ADRB2—polycystic ovary syndrome	0.000409	0.0675	CrCbGaD
Alprenolol—Metoprolol—ADRB2—polycystic ovary syndrome	0.000348	0.0574	CrCbGaD
Alprenolol—Pindolol—ADRB2—polycystic ovary syndrome	0.000322	0.0531	CrCbGaD
Alprenolol—Propranolol—ADRB2—polycystic ovary syndrome	0.000176	0.029	CrCbGaD
Alprenolol—Propranolol—CYP1A1—polycystic ovary syndrome	0.000151	0.0248	CrCbGaD
Alprenolol—HTR1A—Signaling by GPCR—GNRH1—polycystic ovary syndrome	4.4e-05	0.000338	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—SCT—polycystic ovary syndrome	4.39e-05	0.000337	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—PTGER3—polycystic ovary syndrome	4.36e-05	0.000336	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—LHCGR—polycystic ovary syndrome	4.36e-05	0.000336	CbGpPWpGaD
Alprenolol—CYP2D6—Biological oxidations—CYP1A1—polycystic ovary syndrome	4.35e-05	0.000335	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—ADRB2—polycystic ovary syndrome	4.33e-05	0.000333	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—SCT—polycystic ovary syndrome	4.31e-05	0.000332	CbGpPWpGaD
Alprenolol—HTR1A—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	4.31e-05	0.000331	CbGpPWpGaD
Alprenolol—CYP2D6—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	4.29e-05	0.00033	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—LHCGR—polycystic ovary syndrome	4.27e-05	0.000328	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—PTGER3—polycystic ovary syndrome	4.27e-05	0.000328	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—SCT—polycystic ovary syndrome	4.21e-05	0.000324	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	4.2e-05	0.000323	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—MTNR1B—polycystic ovary syndrome	4.18e-05	0.000322	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—PTGER3—polycystic ovary syndrome	4.17e-05	0.000321	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—LHCGR—polycystic ovary syndrome	4.17e-05	0.000321	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	4.11e-05	0.000316	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—FGF18—polycystic ovary syndrome	4.11e-05	0.000316	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	4.11e-05	0.000316	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—PTAFR—polycystic ovary syndrome	4.08e-05	0.000314	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—RBP4—polycystic ovary syndrome	4.08e-05	0.000314	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	4.02e-05	0.000309	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	4.02e-05	0.000309	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—GNAS—polycystic ovary syndrome	4.01e-05	0.000309	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—PTAFR—polycystic ovary syndrome	3.99e-05	0.000307	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	3.96e-05	0.000305	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	3.93e-05	0.000302	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—PTAFR—polycystic ovary syndrome	3.9e-05	0.0003	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	3.87e-05	0.000298	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	3.85e-05	0.000296	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—NMNAT3—polycystic ovary syndrome	3.83e-05	0.000295	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—YAP1—polycystic ovary syndrome	3.81e-05	0.000293	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—ADRA1D—polycystic ovary syndrome	3.79e-05	0.000292	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	3.77e-05	0.00029	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—INHBB—polycystic ovary syndrome	3.76e-05	0.000289	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—GAB1—polycystic ovary syndrome	3.75e-05	0.000289	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—ADRA1B—polycystic ovary syndrome	3.69e-05	0.000284	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—INHBB—polycystic ovary syndrome	3.67e-05	0.000283	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—INHBB—polycystic ovary syndrome	3.59e-05	0.000276	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—INSR—polycystic ovary syndrome	3.59e-05	0.000276	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.51e-05	0.00027	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—LPCAT2—polycystic ovary syndrome	3.5e-05	0.00027	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—SUOX—polycystic ovary syndrome	3.5e-05	0.00027	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.43e-05	0.000264	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.42e-05	0.000263	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.41e-05	0.000262	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3.36e-05	0.000258	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.35e-05	0.000258	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.34e-05	0.000257	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—PGR—polycystic ovary syndrome	3.32e-05	0.000256	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.27e-05	0.000252	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—ISYNA1—polycystic ovary syndrome	3.26e-05	0.000251	CbGpPWpGaD
Alprenolol—CYP2D6—Biological oxidations—POMC—polycystic ovary syndrome	3.25e-05	0.00025	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—FSHR—polycystic ovary syndrome	3.19e-05	0.000246	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—POMC—polycystic ovary syndrome	3.13e-05	0.000241	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—FSHR—polycystic ovary syndrome	3.12e-05	0.00024	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.1e-05	0.000239	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—GHRL—polycystic ovary syndrome	3.09e-05	0.000238	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—PLAT—polycystic ovary syndrome	3.09e-05	0.000238	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—POMC—polycystic ovary syndrome	3.06e-05	0.000235	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—FSHR—polycystic ovary syndrome	3.05e-05	0.000235	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.04e-05	0.000234	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3e-05	0.000231	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—POMC—polycystic ovary syndrome	2.99e-05	0.00023	CbGpPWpGaD
Alprenolol—HTR1A—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	2.98e-05	0.000229	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.98e-05	0.000229	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—GHRL—polycystic ovary syndrome	2.97e-05	0.000228	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—ATF1—polycystic ovary syndrome	2.95e-05	0.000227	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	2.94e-05	0.000226	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	2.92e-05	0.000225	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.87e-05	0.000221	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	2.87e-05	0.000221	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.86e-05	0.00022	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	2.86e-05	0.00022	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—FST—polycystic ovary syndrome	2.85e-05	0.000219	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	2.83e-05	0.000218	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.81e-05	0.000216	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	2.79e-05	0.000215	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—FST—polycystic ovary syndrome	2.78e-05	0.000214	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—LHB—polycystic ovary syndrome	2.78e-05	0.000214	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	2.77e-05	0.000213	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	2.77e-05	0.000213	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.75e-05	0.000212	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—FST—polycystic ovary syndrome	2.72e-05	0.000209	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—NGFR—polycystic ovary syndrome	2.72e-05	0.000209	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—LHB—polycystic ovary syndrome	2.72e-05	0.000209	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.71e-05	0.000209	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	2.71e-05	0.000208	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—POMC—polycystic ovary syndrome	2.7e-05	0.000208	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—PRL—polycystic ovary syndrome	2.7e-05	0.000207	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.69e-05	0.000207	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—LHB—polycystic ovary syndrome	2.66e-05	0.000204	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.66e-05	0.000204	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.63e-05	0.000202	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.62e-05	0.000202	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—SCT—polycystic ovary syndrome	2.6e-05	0.0002	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.6e-05	0.0002	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.6e-05	0.0002	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.57e-05	0.000198	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.57e-05	0.000198	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.57e-05	0.000197	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.56e-05	0.000197	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—SCT—polycystic ovary syndrome	2.55e-05	0.000196	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.52e-05	0.000194	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.51e-05	0.000193	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—SCT—polycystic ovary syndrome	2.49e-05	0.000192	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.48e-05	0.000191	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.46e-05	0.000189	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—FGF18—polycystic ovary syndrome	2.44e-05	0.000188	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.43e-05	0.000187	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—RBP4—polycystic ovary syndrome	2.42e-05	0.000186	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—FGF18—polycystic ovary syndrome	2.39e-05	0.000184	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.38e-05	0.000183	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.38e-05	0.000183	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—GNAS—polycystic ovary syndrome	2.37e-05	0.000182	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—RBP4—polycystic ovary syndrome	2.37e-05	0.000182	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—FGF18—polycystic ovary syndrome	2.33e-05	0.00018	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.33e-05	0.000179	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	2.32e-05	0.000179	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—RBP4—polycystic ovary syndrome	2.31e-05	0.000178	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.28e-05	0.000175	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.26e-05	0.000174	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—YAP1—polycystic ovary syndrome	2.26e-05	0.000174	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—GAB1—polycystic ovary syndrome	2.23e-05	0.000171	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—NRG1—polycystic ovary syndrome	2.22e-05	0.000171	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—YAP1—polycystic ovary syndrome	2.21e-05	0.00017	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	2.2e-05	0.000169	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—GAB1—polycystic ovary syndrome	2.18e-05	0.000168	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—YAP1—polycystic ovary syndrome	2.16e-05	0.000166	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—GAB1—polycystic ovary syndrome	2.13e-05	0.000164	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—INSR—polycystic ovary syndrome	2.13e-05	0.000164	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	2.1e-05	0.000161	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—INSR—polycystic ovary syndrome	2.08e-05	0.00016	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—INSR—polycystic ovary syndrome	2.04e-05	0.000157	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.02e-05	0.000156	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.99e-05	0.000153	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.98e-05	0.000152	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—PGR—polycystic ovary syndrome	1.97e-05	0.000152	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.95e-05	0.00015	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.94e-05	0.000149	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—PGR—polycystic ovary syndrome	1.93e-05	0.000148	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.91e-05	0.000147	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—IRS2—polycystic ovary syndrome	1.9e-05	0.000146	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—PGR—polycystic ovary syndrome	1.89e-05	0.000145	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	1.87e-05	0.000144	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—LEP—polycystic ovary syndrome	1.86e-05	0.000143	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—GHRL—polycystic ovary syndrome	1.83e-05	0.000141	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—PLAT—polycystic ovary syndrome	1.83e-05	0.000141	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—PLAT—polycystic ovary syndrome	1.79e-05	0.000138	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—GHRL—polycystic ovary syndrome	1.79e-05	0.000138	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	1.78e-05	0.000137	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.77e-05	0.000136	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.75e-05	0.000135	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.75e-05	0.000135	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—ATF1—polycystic ovary syndrome	1.75e-05	0.000135	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.73e-05	0.000133	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—ATF1—polycystic ovary syndrome	1.71e-05	0.000132	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.71e-05	0.000131	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.7e-05	0.000131	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.69e-05	0.00013	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—ATF1—polycystic ovary syndrome	1.67e-05	0.000129	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.67e-05	0.000128	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.66e-05	0.000128	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—IRS1—polycystic ovary syndrome	1.66e-05	0.000128	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.63e-05	0.000126	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	1.63e-05	0.000125	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.62e-05	0.000125	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—NGFR—polycystic ovary syndrome	1.61e-05	0.000124	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—POMC—polycystic ovary syndrome	1.6e-05	0.000123	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—PRL—polycystic ovary syndrome	1.6e-05	0.000123	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—POMC—polycystic ovary syndrome	1.6e-05	0.000123	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	1.59e-05	0.000122	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—INS—polycystic ovary syndrome	1.59e-05	0.000122	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	1.58e-05	0.000122	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	1.57e-05	0.000121	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	1.57e-05	0.00012	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—NGFR—polycystic ovary syndrome	1.54e-05	0.000119	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.54e-05	0.000119	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	1.54e-05	0.000119	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—IGF1—polycystic ovary syndrome	1.54e-05	0.000118	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—AKT2—polycystic ovary syndrome	1.53e-05	0.000118	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—POMC—polycystic ovary syndrome	1.53e-05	0.000118	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—PRL—polycystic ovary syndrome	1.53e-05	0.000118	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.52e-05	0.000117	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.51e-05	0.000116	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.48e-05	0.000113	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.46e-05	0.000112	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.45e-05	0.000112	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	1.42e-05	0.000109	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—GNAS—polycystic ovary syndrome	1.41e-05	0.000108	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	1.38e-05	0.000106	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	1.37e-05	0.000106	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.35e-05	0.000104	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.34e-05	0.000103	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	1.32e-05	0.000102	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.32e-05	0.000101	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.31e-05	0.000101	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.29e-05	9.91e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.28e-05	9.87e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	1.27e-05	9.78e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.26e-05	9.69e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	1.26e-05	9.66e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	1.19e-05	9.12e-05	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—IL6—polycystic ovary syndrome	1.17e-05	9.04e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	1.17e-05	8.98e-05	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.13e-05	8.67e-05	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	1.1e-05	8.49e-05	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.1e-05	8.48e-05	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	1.08e-05	8.3e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.08e-05	8.3e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	1.06e-05	8.12e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—TH—polycystic ovary syndrome	1.01e-05	7.77e-05	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1e-05	7.72e-05	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	9.84e-06	7.57e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	9.83e-06	7.56e-05	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	9.63e-06	7.41e-05	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	9.48e-06	7.29e-05	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	9.42e-06	7.25e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	9.41e-06	7.24e-05	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	9.27e-06	7.13e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	9.24e-06	7.11e-05	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	9.22e-06	7.09e-05	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	9.12e-06	7.01e-05	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	9.11e-06	7.01e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	9.07e-06	6.97e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	9.02e-06	6.94e-05	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	8.92e-06	6.86e-05	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	8.91e-06	6.86e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	8.72e-06	6.71e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	8.71e-06	6.7e-05	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.66e-06	6.66e-05	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.47e-06	6.52e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.28e-06	6.37e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	8.25e-06	6.34e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	7.86e-06	6.04e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	7.45e-06	5.73e-05	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	6.97e-06	5.36e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	6.94e-06	5.34e-05	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—IL6—polycystic ovary syndrome	6.94e-06	5.34e-05	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	6.82e-06	5.25e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	6.67e-06	5.13e-05	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.95e-06	4.58e-05	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.82e-06	4.48e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.7e-06	4.38e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	5.63e-06	4.33e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	5.55e-06	4.27e-05	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—INS—polycystic ovary syndrome	5.52e-06	4.25e-05	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	4.12e-06	3.17e-05	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	4.03e-06	3.1e-05	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	3.94e-06	3.03e-05	CbGpPWpGaD
